Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
40 hedge funds and large institutions have $120M invested in Landos Biopharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
14% more funds holding
Funds holding: 35 → 40 (+5)
5.48% more ownership
Funds ownership: 56.52% → 62% (+5.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
64% less capital invested
Capital invested by funds: $331M → $120M (-$211M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.49M |
| 2 |
Renaissance Technologies
New York
|
+$1.68M |
| 3 |
Morgan Stanley
New York
|
+$1.6M |
| 4 |
Walleye Capital
New York
|
+$1.11M |
| 5 |
Two Sigma Investments
New York
|
+$576K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$3.11M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.82M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$315K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$275K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$265K |
LABP Hedge Fund Activity: Q4 2021 in Review
40 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q4 2021, worth a combined $120M — down 64% from $331M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new LABP positions and 6 closed out — a net gain of 5 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $2.49M. The largest seller was Woodline Partners, exiting entirely with an estimated $3.11M sold.
- 40 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q4 2021, up from 35 in Q3 2021.
- Funds reported $120M of Landos Biopharma, Inc. Common Stock stock for Q4 2021, down 64% quarter-over-quarter.
- 11 funds opened new Landos Biopharma, Inc. Common Stock positions in Q4 2021 and 6 closed out, a net change of +5 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $2.49M added.
- The largest Landos Biopharma, Inc. Common Stock seller in Q4 2021 was Woodline Partners, an estimated $3.11M sold.
Based on aggregated 13F filings for Q4 2021.